FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial
Sebastian Stintzing(Humboldt-Universität zu Berlin), Volker Heinemann(LMU Klinikum), Alexander Kiani(Bayreuth Medical Center), Thomas Decker, Markus Moehler(Johannes Gutenberg University Mainz), A. Jagenburg, Martina Stauch, Ursula Vehling‐Kaiser(University of Applied Sciences Landshut), Dominik Paul Modest(Berliner Hochschule für Technik), Swantje Held(AIO Studien gGmbH), Andreas Jung(Ludwig-Maximilians-Universität München), Christoph Kahl(Klinikum Magdeburg), Salah‐Eddin Al‐Batran(Goethe University Frankfurt), Tobias Heintges(Lukaskrankenhaus), Lisa Rossius(München Klinik), Ludwig Fischer von Weikersthal(Praxis für Hämatologie und Onkologie), Markus M. Lerch(Ludwig-Maximilians-Universität München), Werner Scheithauer(Comprehensive Cancer Center Vienna), G. Seipelt, Christian Lerchenmüller, Clemens Gießen-Jung, Frank Kullmann(Klinikum Weiden), Thomas Kirchner(Friedrich-Alexander-Universität Erlangen-Nürnberg)
Cited by 417
Related Papers
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial
|The Lancet|2008|1.9k
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
|New England Journal of Medicine|2021|1.7k